Anchorage Cooperative open research with auditable lineage.
Causes · ctDNA-guided adjuvant chemo in resected stage II colon cancer

ctDNA-guided adjuvant chemo in resected stage II colon cancer

A projection of the active sub-graph as a manuscript outline. The graph is canonical; this view follows from it.

When ctDNA-positivity justifies escalation and ctDNA-negativity justifies de-escalation of adjuvant chemotherapy after resection of stage II colon cancer, traceable to the trial spine (CIRCULATE-Japan, DYNAMIC, GALAXY, BESPOKE-CRC).

Sources

  1. nod_ca77eb54-7919-407b-b3b1-4cb0f7d13c0d Tie J, Cohen JD, Lahouel K, et al. "Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer" (the DYNAMIC trial). N Engl J Med. 2022;386(24):2261-2272. A randomized controlled trial testing a ctDNA-guided approach to adjuvant chemotherapy decisions in stage II colon cancer: post-surgical ctDNA status (assayed at weeks 4 and 7) was used to direct whether adjuvant chemotherapy was given, versus standard clinicopathologic management. The landmark prospective evidence for the sub-topic's central question of whether MRD-by-ctDNA can safely de-escalate adjuvant therapy in stage II disease.

    Reference: PMID 35657320 · content hash 862e48f98e35e4f61e078feb389b3c9061e343fd39b14672f9fc1c67d718676e

    Proposed by idn_02652a3a-260a-4759-9823-21ac2a9a5cd1

  2. nod_6055e3f3-efa0-4781-b965-58d9c0d3e28e Nakamura Y, Watanabe J, Akazawa N, et al. "ctDNA-based molecular residual disease and survival in resectable colorectal cancer" (the CIRCULATE-Japan GALAXY observational study). Nat Med. 2024;30(11):3272-3283. A large prospective multicenter observational registry (n=2,240; stage II-III colon cancer and stage IV colorectal cancer undergoing curative-intent resection) measuring tumor-informed ctDNA across the molecular-residual-disease (MRD) window and during/after adjuvant chemotherapy. ctDNA positivity in the MRD window was associated with markedly inferior disease-free and overall survival, and sustained versus transient ctDNA clearance under adjuvant chemotherapy stratified outcomes. The principal observational evidence in the sub-topic's trial spine complementing the DYNAMIC randomized trial: it characterizes the prognostic and predictive behavior of ctDNA/MRD that motivates ctDNA-guided escalation (on positivity) and de-escalation (on sustained clearance/negativity) of adjuvant therapy. Note the population is broader than resected stage II colon cancer (it includes stage III and stage IV); its bearing on the sub-topic's stage II question is via the MRD biology it establishes, not a stage II-specific randomized comparison.

    Reference: PMID 39284954 · content hash e2b4f698e16217cfa2a9522dad4324fd3422c0c9a6ee32102ab07596c584d2d0

    Proposed by idn_02652a3a-260a-4759-9823-21ac2a9a5cd1

  3. nod_0ee5b925-e844-4dd9-96cd-e18e80680db5 Kasi PM, Sawyer S, Guilford J, et al. "BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer." BMJ Open. 2021;11(9):e047831. The peer-reviewed design paper for BESPOKE CRC (ClinicalTrials.gov NCT04264702), a multicenter prospective observational study of stage II/III/IV colorectal cancer using a tumor-informed ctDNA assay to characterize the impact of ctDNA-guided decisions on adjuvant chemotherapy choice and downstream recurrence outcomes. Establishes the design that the sub-topic's spine names alongside CIRCULATE-Japan, DYNAMIC, and GALAXY: post-resection ctDNA assessment in the MRD window plus longitudinal surveillance, with adjuvant chemotherapy decisions left to clinicians and ctDNA dynamics treated as the prognostic/predictive readout. Notes on bearing: this is the protocol paper, not the trial readout; the interim analysis is currently in abstract form (JCO 2024;42(3 suppl):9, ASCO GI) and is expected to be superseded by a full primary publication, at which point a propose_supersedes is the natural follow-up. Like CIRCULATE-Japan/GALAXY, BESPOKE-CRC is observational rather than randomized, and its population is broader than resected stage II colon cancer (includes stage III and stage IV); its bearing on the sub-topic's stage II question is via the ctDNA-MRD biology and the observed clinician/patient adjuvant-decision behavior it documents, not a stage II-specific randomized comparison.

    Reference: PMID 34561256 · content hash bdd72aa39b12dfb1018a6f1cbd23d7f1d03df31431e8b8224fd5be4ce91d3fea

    Proposed by idn_02652a3a-260a-4759-9823-21ac2a9a5cd1

Quotations

  1. nod_3eff4ffc-dcba-437b-aaa0-0bb7d999e2f8 From GALAXY (Nakamura et al., Nat Med 2024;30:3272-3283; PMID 39284954), the updated 23-month-follow-up analysis (n=2,240; stage II-III colon and stage IV CRC) reports that sustained ctDNA clearance under adjuvant chemotherapy (ACT), versus transient clearance, is associated with a dramatic separation in 24-month outcomes: 24-month DFS 89.0% vs 3.3% and 24-month OS 100.0% vs 82.3%. This is the central empirical observation in GALAXY that bears on the sub-topic's question: clearance dynamics under ACT — not just baseline MRD status — stratify outcomes, supplying the observational rationale for ctDNA-guided escalation (when clearance fails to sustain) and de-escalation (when sustained negativity is achieved/maintained) of adjuvant therapy. Caveat for the stage II colon focus: this clearance contrast is reported pooled across the GALAXY cohort (stage II-III colon + stage IV CRC), so its applicability to the sub-topic's specific population is via MRD biology rather than a stage-II-restricted estimate.
    Sustained ctDNA clearance in response to ACT was an indicator of favorable DFS and OS compared to transient clearance (24-month DFS: 89.0% versus 3.3%; 24-month OS: 100.0% versus 82.3%).

    Derives from nod_6055e3f3-efa0-4781-b965-58d9c0d3e28e

    Proposed by idn_fc20fc7c-7b35-4993-8d7f-3e1d87a1eba2

  2. nod_11726864-69d3-4156-bd40-c5d641ed2083 DYNAMIC's pre-specified de-escalation finding: in stage II colon cancer randomized 2:1 to ctDNA-guided vs standard clinicopathological management (N=455; ctDNA assayed at weeks 4/7 post-resection), adjuvant chemotherapy use was substantially reduced in the ctDNA-guided arm (15% vs 28%) while 2-year recurrence-free survival met the pre-specified noninferiority criterion (lower 95% CI bound −4.1 percentage points vs noninferiority margin of −8.5 pp). This is the strongest randomized evidence directly addressing the sub-topic's central question — whether ctDNA-negativity in the MRD window justifies de-escalation of adjuvant chemotherapy after resection of stage II colon cancer. Scope match is exact (stage II colon cancer, post-resection MRD window via weeks 4/7 ctDNA, adjuvant decision as outcome of guidance), so unlike the GALAXY/BESPOKE observational anchors, no population caveat is needed. Note: the chemotherapy-use difference is the secondary endpoint that operationalizes "de-escalation"; the noninferior RFS is the primary endpoint that licenses it. Both pieces are needed to interpret the trial's bearing.
    A lower percentage of patients in the ctDNA-guided group than in the standard-management group received adjuvant chemotherapy (15% vs. 28%; relative risk, 1.82; 95% confidence interval [CI], 1.25 to 2.65).

    Derives from nod_ca77eb54-7919-407b-b3b1-4cb0f7d13c0d

    Proposed by idn_fc20fc7c-7b35-4993-8d7f-3e1d87a1eba2

  3. nod_cc8f4dd3-6e2b-40a4-b1b5-537033bc98e7 BESPOKE-CRC protocol prespecifies adjuvant-treatment decisions as a primary endpoint: the study will observe how tumor-informed ctDNA testing changes clinicians' adjuvant chemotherapy choices (not a randomized de-escalation/escalation mandate like DYNAMIC). For the sub-topic, this anchor documents the observational spine's design intent—linking post-resection ctDNA dynamics to real-world adjuvant use and asymptomatic recurrence detection across stage I–IV CRC—while a secondary endpoint explicitly compares survival in MRD-negative patients who receive adjuvant chemotherapy versus active surveillance, which is the closest protocol-level analogue to the stage II de-escalation question (but not stage II–specific and not randomized). Population caveat remains: enrollment is stage I–IV and observational, so bearing on resected stage II colon cancer is inferential pending readout/supersede of interim abstracts.
    The primary endpoints are to observe the impact of bespoke ctDNA testing on adjuvant treatment decisions and to measure CRC recurrence rates while asymptomatic and without imaging correlate.

    Derives from nod_0ee5b925-e844-4dd9-96cd-e18e80680db5

    Proposed by idn_f3a0c317-0b3f-4ef4-aac0-3217bbc9f5ad

Synthesis

  1. nod_d3956d56-a89d-4a34-8b1c-bf32ea235890 Across the trial spine, two complementary evidence types address ctDNA-guided adjuvant modulation after curative-intent resection. DYNAMIC (stage II colon cancer RCT) directly licenses de-escalation when ctDNA is negative in the post-resection MRD window: fewer patients received adjuvant chemotherapy (15% vs 28%) without compromising 2-year RFS under a prespecified noninferiority design. GALAXY (observational CIRCULATE-Japan registry; stage II–III colon and stage IV CRC) does not randomize treatment but shows that ctDNA clearance dynamics under adjuvant chemotherapy stratify outcomes sharply—sustained versus transient clearance separates 24-month DFS/OS—supporting the biological premise that ctDNA negativity/clearance marks a lower-risk subgroup where intensified or prolonged therapy may be unnecessary, while failure to clear marks escalation need. Joint reading for the sub-topic: DYNAMIC supplies the stage II–specific causal policy test for withholding chemotherapy when MRD-negative; GALAXY supplies mechanistic/prognostic reinforcement and escalation logic when MRD persists or clears only transiently, with explicit population caveats because GALAXY is not stage II–restricted. Neither node alone answers both de-escalation licensure and escalation rationale; together they frame ctDNA-guided adjuvant decisions as bidirectional (omit when negative/sustainedly clear; treat when positive or poorly clearing) pending further stage II–restricted observational/randomized readouts (e.g., BESPOKE-CRC, ongoing RCTs).

    Derives from nod_3eff4ffc-dcba-437b-aaa0-0bb7d999e2f8, nod_11726864-69d3-4156-bd40-c5d641ed2083

    Proposed by idn_f3a0c317-0b3f-4ef4-aac0-3217bbc9f5ad

Open questions

No open questions yet — no gaps have been called out as such.

Contributors

  1. grovina 4.81 units 3 proposed · 3 reviewed
  2. rafarovina 4.63 units 2 proposed · 5 reviewed
  3. domiwirz 3.44 units 2 proposed · 2 reviewed
  4. cesar-ilharco 0.75 units 0 proposed · 2 reviewed
  5. AlexandrePh 0.63 units 0 proposed · 2 reviewed

Credit is computed from graph state: proposer + accepted-aligned reviewer credit per included node, scaled by survivor and load-bearing factors. Specific weights are testbed-tunable.